Cefiderocol use in Gram negative infections with limited therapeutic options: Is combination therapy the key?

Objectives: To date limited information about cefiderocol use is provided by real life studies. Our aim is to evaluate characteristics and outcome of patients with Gram-negative infections with limited therapeutic options treated with cefiderocol in combination or monotherapy. Methods: We retrospect...

Full description

Bibliographic Details
Published in:	Journal of Infection and Public Health
Main Authors:	Silvia Corcione, Ilaria De Benedetto, Simone Mornese Pinna, Davide Vita, Tommaso Lupia, Giorgia Montrucchio, Luca Brazzi, Francesco Giuseppe De Rosa
Format:	Article
Language:	English
Published:	Elsevier 2022-09-01
Subjects:	Cefiderocol Gram negative bacteria Acinetobacter baumannii VAP Combination therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S187603412200185X

Similar Items

Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections
by: Amer El Ghali, et al.
Published: (2024-02-01)

EFFICACY OF COLISTIN AND CEFIDEROCOL ON CARBAPENEM RESISTANT Acinetobacter baumannii ISOLATES
by: Feyza Balci, et al.
Published: (2024-12-01)

The solution to drug resistance of Gram-negative bacteria – Cefiderocol
by: Magdalena Kołodziej, et al.
Published: (2023-05-01)

Real-Life Data on the Effectiveness and Safety of Cefiderocol in Severely Infected Patients: A Case Series
by: Ángel Marcos Fendian, et al.
Published: (2023-03-01)

Acinetobacter Baumannii – Virulence Factors and Epidemiology of Infections
by: Marszalik Anna, et al.
Published: (2021-12-01)

Cefiderocol-Based Regimen for Acinetobacter NDM-1 Outbreak
by: Giovanna Travi, et al.
Published: (2024-08-01)

Meropenem/Vaborbactam and Cefiderocol as Combination or Monotherapy to Treat Multi-Drug Resistant Gram-Negative Infections: A Regional Cross-Sectional Survey from Piedmont Infectious Disease Unit Network (PIDUN)
by: Tommaso Lupia, et al.
Published: (2022-10-01)

Real-life experience with cefiderocol for the treatment of difficult-to-treat gram-negative infections
by: L. Ybañez García, et al.
Published: (2023-07-01)

Challenges Facing Two Outbreaks of Carbapenem-Resistant <i>Acinetobacter baumannii</i>: From Cefiderocol Susceptibility Testing to the Emergence of Cefiderocol-Resistant Mutants
by: Montserrat Rodríguez-Aguirregabiria, et al.
Published: (2024-08-01)

Genomic characterization of an NDM-9-producing Acinetobacter baumannii clinical isolate and role of Glu152Lys substitution in the enhanced cefiderocol hydrolysis of NDM-9
by: Susie Gaillot, et al.
Published: (2023-08-01)

In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program
by: Dee Shortridge, et al.
Published: (2022-04-01)

Efficacy of Cefiderocol Against Endophthalmitis Isolates
by: Brennan Schilling, et al.
Published: (2024-12-01)

Cefiderocol-Based Combination Therapy for “Difficult-to-Treat” Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives
by: Davide Fiore Bavaro, et al.
Published: (2021-05-01)

The Use of Cefiderocol in Gram-Negative Bacterial Infections at International Medical Center, Jeddah, Saudi Arabia
by: Reham Kaki, et al.
Published: (2024-11-01)

Intravenous Fosfomycin: A Potential Good Partner for Cefiderocol. Clinical Experience and Considerations
by: Andrea Marino, et al.
Published: (2022-12-01)

Synergistic Activity of Cefiderocol in Combination with Avibactam, Sulbactam or Tazobactam against Carbapenem-Resistant Gram-Negative Bacteria
by: Russell E. Lewis, et al.
Published: (2024-08-01)

Pharmacokinetic of Cefiderocol in Critically Ill Patients Receiving Renal Replacement Therapy: A Case Series
by: Simone Mornese Pinna, et al.
Published: (2022-12-01)

Comparison of cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review with meta-analysis and trial sequential analysis
by: Yangyang Zhan, et al.
Published: (2024-09-01)

Efficacy and safety of cefiderocol in the treatment of infections caused by Gram-negative bacteria: a systematic review and meta-analysis
by: Xiaocui Huang, et al.
Published: (2024-12-01)

Cefiderocol in Combating Carbapenem-Resistant <i>Acinetobacter baumannii</i>: Action and Resistance
by: Bahman Yousefi, et al.
Published: (2024-11-01)

Potential Use of Cefiderocol and Nanosilver in Wound Dressings to Control Multidrug-Resistant Gram-Negative Bacteria
by: Żaneta Binert-Kusztal, et al.
Published: (2025-07-01)

Killing two birds with one stone: emergence of colistin and cefiderocol resistance in a mucoid MDR Acinetobacter baumannii under colistin pressure
by: Valeria Fox, et al.
Published: (2025-09-01)

Should we, and how to, optimize cefiderocol administration during severe nosocomial pneumonia due to carbapenem-resistant Acinetobacter baumanii? A viewpoint
by: Julien Massol, et al.
Published: (2024-09-01)

Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms
by: Monirul I. Sajib, et al.
Published: (2023-05-01)

In Vitro Activity of Cefiderocol Compared to Other Antimicrobials against a Collection of Metallo-Beta-Lactamase-Producing Gram-Negative Bacilli from Southern Spain
by: M. Delgado-Valverde, et al.
Published: (2023-06-01)

Cefiderocol Versus Best Available Therapy in the Treatment of Critically Ill Patients with Severe Infections Due to Resistant Gram-Negative Bacteria: A Systematic Review and Meta-Analysis
by: Carlos Risco-Risco, et al.
Published: (2024-11-01)

Adaptive resistance to cefiderocol in carbapenem-resistant Acinetobacter baumannii (CRAB): microbiological and clinical issues
by: Anissa Desmoulin, et al.
Published: (2024-05-01)

Heteroresistance to cefiderocol in carbapenem-resistant Acinetobacter baumannii in the CREDIBLE-CR study was not linked to clinical outcomes: a post hoc analysis
by: Christopher Longshaw, et al.
Published: (2023-12-01)

In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals
by: John H. Kimbrough, et al.
Published: (2024-11-01)

SUSCETIBILIDADE DE CEFIDEROCOL ENTRE PSEUDOMONAS AERUGINOSA E COMPLEXO ACINETOBACTER BAUMANNII (CAB) EM HOSPITAL TERCIÁRIO DE PORTO ALEGRE
by: Deise Reis Carvalho, et al.
Published: (2023-10-01)

In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO‑WT‑2014−2018 studies in Spain
by: Emilia Cercenado, et al.
Published: (2021-09-01)

Erratum: Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence
by: Frontiers Production Office
Published: (2022-08-01)

Cefiderocol Versus Colistin for the Treatment of Carbapenem-Resistant Acinetobacter baumannii Complex Bloodstream Infections: A Retrospective, Propensity-Score Adjusted, Monocentric Cohort Study
by: Davide Fiore Bavaro, et al.
Published: (2023-09-01)

In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against <i>Acinetobacter baumannii</i> Strains Recovered from Clinical Samples
by: Davide Carcione, et al.
Published: (2021-10-01)

Assessment of the Anti-Biofilm Effect of Cefiderocol Against 28 Clinical Strains of Multidrug-Resistant Gram-Negative Bacilli
by: Marta Díaz-Navarro, et al.
Published: (2025-07-01)

Human Serum Proteins and Susceptibility of <i>Acinetobacter baumannii</i> to Cefiderocol: Role of Iron Transport
by: Casin Le, et al.
Published: (2022-03-01)

Susceptibility toward cefiderocol and sulbactam-durlobactam in extensively drug-resistant Acinetobacter baumannii detected from ICU admission screening in Hanoi, Vietnam, 2023
by: Sébastien Boutin, et al.
Published: (2025-07-01)

Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of <i>Acinetobacter baumannii</i> Clinical Isolates
by: Clara Ballesté-Delpierre, et al.
Published: (2022-01-01)

Resistance to Cefiderocol Involved Expression of PER-1 β-Lactamase and Downregulation of Iron Transporter System in Carbapenem-Resistant Acinetobacter baumannii
by: He Y, et al.
Published: (2022-12-01)

Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol
by: Gabriele Bianco, et al.
Published: (2024-12-01)